Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.21% | 11.31% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.21% | 11.31% | |||
| Cost of Revenue | 1.31% | 11.43% | |||
| Gross Profit | -0.75% | 11.20% | |||
| SG&A Expenses | -0.39% | 5.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.27% | 8.23% | |||
| Operating Income | -14.57% | 39.89% | |||
| Income Before Tax | -204.13% | 396.40% | |||
| Income Tax Expenses | -192.72% | 395.88% | |||
| Earnings from Continuing Operations | -207.58% | 396.56% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -207.58% | 396.56% | |||
| EBIT | -14.57% | 39.89% | |||
| EBITDA | -6.66% | 26.53% | |||
| EPS Basic | -208.79% | 409.61% | |||
| Normalized Basic EPS | -10.59% | -1.27% | |||
| EPS Diluted | -208.83% | 409.61% | |||
| Normalized Diluted EPS | -10.59% | -1.23% | |||
| Average Basic Shares Outstanding | -1.11% | -2.56% | |||
| Average Diluted Shares Outstanding | -1.12% | -2.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||